Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guardant HealthGH +0.57%65 EV-to-EBIT is -49.12 as of Aug. 04, 2026. GuruFocus rates GH with a GF Score™ of 65/100 and a GF Value™ of $65.16 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 105 Medical Diagnostics & Research companies, Guardant Health ranks worse than 952380% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Guardant Health's Enterprise Value for the quarter that ended in Jun. 2026 was $20,690 Mil.
Guardant Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-450 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guardant Health EV-to-EBIT Related Terms
Guardant Health EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Guardant Health's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Guardant Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Guardant Health's EV-to-EBIT falls into.
Guardant Health's current Enterprise Value is $22,087 Mil.
Guardant Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-450 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guardant Health (GH) has a EV-to-EBIT of -49.12 as of Aug. 04, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Guardant Health and its competitors. According to the industry distribution chart, Guardant Health ranks #999999 out of 105 companies in the Medical Diagnostics & Research industry.
Is Guardant Health's EV-to-EBIT too high?
Guardant Health's current EV-to-EBIT is -49.12. Based on the distribution chart, Guardant Health ranks #999999 out of 105 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Guardant Health has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guardant Health's EV-to-EBIT compare to MEDP and LH?
According to the Medical Diagnostics & Research industry distribution chart, Guardant Health ranks #999999 out of 105 companies for EV-to-EBIT. This places Guardant Health in the lower half of its industry. The industry median EV-to-EBIT is 22.77. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 22.77, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Guardant Health and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 22.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guardant Health's current EV-to-EBIT is -49.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guardant Health stock overvalued right now?
Based on GuruFocus' analysis, Guardant Health (GH) is currently considered Significantly Overvalued. The stock's GF Value™ is $65.16, compared to a current price of $159.84 — trading 145.3% above its estimated fair value. The current EV-to-EBIT is -49.12. Guardant Health's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Guardant Health (GH), the current EV-to-EBIT is -49.12 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guardant Health (GH) Overvalued in 2026?
Based on GuruFocus' analysis, Guardant Health stock appears to be overvalued.
The current stock price of $159.84 is trading 145.3% above its estimated GF Value™ of $65.16.
GuruFocus considers Guardant Health to be Significantly Overvalued.
Key valuation signals for GH:
EV-to-EBIT: -49.12
GF Value™: $65.16 vs. price of $159.84 (145.3% above fair value)
No single metric tells the full story. See the GH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
65GF Score
Get the complete analysis for GH
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GH has been successfully added to your 
